Coeptis Therapeutics, Inc. (COEP)
Company Description
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer.
Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies.
The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease.
Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Mr. David Mehalick |
Contact Details
Address:
105 Bradford Rd, Suite 420 Wexford, Pennsylvania 15090 United States | |
| Phone | 724-934-6467 |
| Website | coeptispharma.com |
Stock Details
| Ticker Symbol | COEP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819663 |
| CUSIP Number | 19207C104 |
| ISIN Number | US19207C1045 |
| Employer ID | 84-3998117 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Mehalick | Co-Founder, Chairman, Chief Executive Officer and Pres |
| Christine Elise Sheehy | Co-Founder, Chief Financial Officer and Secretary |
| Daniel Alexander Yerace | Co-Founder, Vice President of Operations and Director |
| Gary R. Conte | Senior Vice President of Sales and Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 14, 2022 | 15-12G | Securities registration termination |
| Nov 8, 2022 | 10-Q | Quarterly Report |
| Oct 28, 2022 | 8-K | Current Report |
| Sep 30, 2022 | DEFM14A | Filing |
| Sep 21, 2022 | 8-K | Current Report |
| Sep 21, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 19, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 16, 2022 | PREM14A | Filing |
| Sep 7, 2022 | 253G2 | Acc-no: 0001493152-21-027927 (33 Act) |
| Sep 7, 2022 | 8-K | Current Report |